IDEXX Laboratories reported second quarter 2026 revenue of $1,217 million, a 10% increase as reported and 9% organic, driven by growth in Companion Animal Group, Water, and Livestock, Poultry and Dairy segments. Diluted earnings per share reached $4.27, up 18% as reported and 15% on a comparable basis. The company raised its full-year 2026 revenue guidance to $4,700 million - $4,745 million and increased the EPS outlook to $14.69 - $14.94. IDEXX Laboratories operates in the veterinary diagnostics and pet healthcare industry.
